Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Appointed director
Consulting agrmnt
Director departure
|
|
THERALINK TECHNOLOGIES, INC. (OBMP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer Golden, Colorado, June 27, 2023 — Theralink Technologies, Inc. , a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. , today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’ s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’ s Chief Medical Officer. “I am very excited to hand the reins to Faith as we take the strategic step to merge with IMAC,” commented Dr. Ruxin. “As we begin a new chapter of shifting our focus from research and d..." |
|
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2023 |
8-K
| Quarterly results |
| 12/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/01/2022 |
8-K
| Quarterly results |
| 09/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/11/2022 |
8-K/A
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 02/03/2022 |
8-K
| Quarterly results |
| 01/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/05/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"THERALINK TECHNOLOGIES, INC. 2021 CONVERTIBLE PROMISSORY NOTE $[ ] Golden, Colorado Issue Date: NOVEMBer [ ], 2021",
"COMMON STOCK PURCHASE WARRANT THERALINK TECHNOLOGIES, inc. Warrant Shares: [ ] Issue Date: November [ ], 2021 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [ ] is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date and upon the CUSIP eligibility of the Warrant Shares and on or prior to the close of business on the Termination Date but not thereafter, to subscribe for and purchase from Theralink Technologies, Inc., a Nevada corporation , of up to [ ] shares of the Company’ s Common Stock, par value $0.0001 per share . This Warrant is being issued in connection with the Securities Purchase Agreement, dated November [ ], 2021 by and between the Company and the Holder pursuant t...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 1, 2021, between Theralink Technologies, Inc., a Nevada corporation , and each investor identified on the signature pages to this Agreement . WHEREAS, the Company is seeking to raise a maximum of $3 million in an offering of Notes and Warrants to investors ; WHEREAS, the Investor desires to purchase from the Company a convertible promissory note, in the form attached hereto as Exhibit A , which Note shall be convertible into the Company’ s common stock, par value $0.0001 per share , in accordance with its terms; WHEREAS, in connection with the Offering, the Company will issue warrants to purchase shares of Common Stock in an amount equal to 20% of the number of the total shares of Common Stock converti..." |
|
| 08/06/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 06/08/2021 |
8-K
| Quarterly results |
| 05/18/2021 |
8-K
| Quarterly results |
| 04/20/2021 |
8-K/A
| Quarterly results |
| 04/20/2021 |
8-K
| Quarterly results |
| 04/20/2021 |
8-K
| Quarterly results |
| 09/29/2020 |
8-K
| Quarterly results |
| 09/21/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 08/26/2020 |
8-K
| Quarterly results |
| 08/19/2020 |
8-K/A
| Quarterly results |
| 06/11/2020 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"Certificate of Designation for Series C-1 Convertible Preferred Stock",
"Certificate of Designation for Series C-2 Convertible Preferred Stock",
"Certificate of Designation for Series D-2 Convertible Preferred Stock",
"Certificate of Designation for Series D-1 Convertible Preferred Stock",
"Certificate of Withdrawal of Certificate of Designation",
"Form of Warrant",
"Exchange Warrant",
"Exchange Agreement, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein",
"Exchange Agreement, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein",
"Exchange Agreement, by and between OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, Ph.D" |
|
| 06/01/2020 |
8-K
| Appointed a new director |
| 05/13/2020 |
8-K
| Quarterly results |
| 05/08/2020 |
8-K
| Quarterly results |
| 09/13/2019 |
8-K
| Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 07/18/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/02/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/19/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/21/2019 |
8-K/A
| Quarterly results |
| 02/04/2019 |
8-K
| Quarterly results |
|
|
|